Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies

Dean Quinn, Christopher N. Barnes, Wayne Yates, David L. Bourdet, Edmund J. Moran, Peter Potgieter, Andrew Nicholls, Brett Haumann*, Dave Singh

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science